Diabetes Pipeline Insight Report 2023 | Major Companies- Janssen Biotech, Kamada, Adocia, Novo Nordisk, and others

DelveInsight's, "Diabetes Pipeline Insights, 2023," report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in Diabetes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

In the Diabetes Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Autistic disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Key takeaways from the Diabetes Pipeline Report

• DelveInsight's Diabetes pipeline report depicts a robust space with 200+ active players working to develop 200+ pipeline therapies for diabetes treatment.

• The leading Diabetes Companies include Daewoong Tradipitant, Janssen Biotech, Zealand Pharma, Provention Bio, BioRestorative Therapies, Elevian, Kamada, Adocia, Oramed Pharmaceuticals, ImCyse, Histogen, Novo Nordisk, Enthera, ActoBio Therapeutics, Japan Tobacco, Avotres, and others

• Promising Diabetes Pipeline Therapies include Enavogliflozin, Golimumab, Dasiglucagon, ThermoStem, rGDF11, IMCY-0098, Insulin icodec, CagriSema, FDC Sema-OW GIP, SemaDapa FDC, ENT-001, AG019, JTT-662, AVT-001, AZD-0186, Cotadutide, LABP-111, VX-880, Encapsulated islet cell program, CPP-1X-T, REMD-477, AT-1501, LY 3209590, Orforglipron, LY3437943, Mazdutide, Peptide YY analogue agonist, GIPR agonist long acting, GIPR Agonist Long Acting II, LY 3493269, NNC0363-0845, Diamyd, ProTrans, VC-02, OPT101, Ladarixin, ILT-101, Stem Cell Educator Therapy, ORMD-0801, Golimumab, JAG301, SQZ TAC research program, VCTX 211, and others.

• The Diabetes Companies and academics are working to assess challenges and seek opportunities that could influence Diabetes R&D. The therapies under development are focused on novel approaches for Diabetes.
Request a sample and discover the recent advances in Diabetes Drug Treatment @ Diabetes Pipeline Report- https://www.delveinsight.com/sample-request/diabetes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Diabetes Overview
Diabetes is a chronic disease that occurs when the pancreas does not produce enough insulin or alternatively, when the body cannot effectively use the insulin it produces. The vast majority of Diabetes can be classified as either type 1 or type 2 diabetes. Type 1 diabetes is an autoimmune disease is characterized by a lack of insulin production by the pancreas.

Recent Developmental Activities in the Diabetes Treatment Landscape

• In February 2023, Genprex, Inc. announced that data highlighting the potential of its gene therapy for Type 1 diabetes was being presented by its research collaborators at the University of Pittsburgh at the four-day International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2023).These results were compelling as they demonstrated the potential for this gene therapy to create newly formed beta-like cells that can produce insulin. They also validated earlier studies of this approach in diabetic mouse models that showed restoration of normal blood glucose levels for several months.

• In February 2023, Provention Bio, Inc. announced the closing of the $35 million equity investment from Sanofi US under the previously announced Co-Promotion Agreement and Securities Purchase Agreement (the "Purchase Agreement").Pursuant to the Purchase Agreement, Sanofi purchased 2,712,497 shares of the Company's common stock, par value $0.0001 per share, at a price of $12.90 per share, representing a total investment of $35 million.

• In January 2023, iTolerance, Inc. announced it has entered into a Master Services Agreement (MSA) with the Diabetes Research Institute (DRI) at the University of Miami Miller School of Medicine, for the advancement of its novel iTOL-100 platform technology as a potential cure for Type 1 Diabetes.

• In November 2022, Biocon Limited announced the signing of a semi-exclusive partnership agreement with Zentiva, a leading pharmaceutical company in Europe, for the commercialization of its vertically integrated, complex formulation, Liraglutide, a drug-device combination for the treatment and management of Type 2 diabetes and obesity.Under the terms of this agreement, Biocon is responsible for the manufacturing and supply of Liraglutide to Zentiva for its commercialization across 30 countries in Europe. Biocon also retained the right to commercialize this product under its own brand in the region.

• In November 2022, The US Food and Drug Administration (FDA) approved Provention Bio's biologics license application (BLA) for Tzield (teplizumab-mzwv) to treat type 1 diabetes (T1D) patients. The anti-CD3-directed antibody Tzield aims to delay the onset of Stage 3 T1D in adults and children aged eight years and above who are currently with stage 2 T1D.

Find out more information of the latest Drugs Launch, News, and Breakthroughs of the Diabetes Pipeline Report @ Latest Diabetes Drugs Launch- https://www.delveinsight.com/sample-request/diabetes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Diabetes Emerging Drugs Profile

• Enavogliflozin - Daewoong
Enavogliflozin (DWP 16001) is an orally available small molecule and sodium glucose transporter 2 inhibitor. The molecule is in phase-3 clinical trials for type-2 diabetic treatment. Enavogliflozin demonstrates the lowering of blood sugar and safety in diabetic patients in phase 2 clinical trials.

• Golimumab - Janssen Biotech
Golimumab is a human IgG1 monoclonal antibody, derived from immunizing genetically engineered mice with human TNFα. It inhibits soluble and transmembrane forms of TNF-α by binding to their specific receptors and blocking in consequence their bioactivity. It is currently under Phase II development for the treatment of Type 1 diabetes mellitus.

Diabetes Pipeline Therapeutics Assessment
There are approx. 200+ key companies which are developing the therapies for Diabetes. The companies which have their Diabetes drug candidates in the most advanced stage, i.e. phase III include, Daewoong.

Learn more about the emerging Diabetes Pipeline Therapies @ Diabetes Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/diabetes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Diabetes Pipeline Report

• Coverage- Global

• Diabetes Companies- Daewoong Tradipitant, Janssen Biotech, Zealand Pharma, Provention Bio, BioRestorative Therapies, Elevian, Kamada, Adocia, Oramed Pharmaceuticals, ImCyse, Histogen, Novo Nordisk, Enthera, ActoBio Therapeutics, Japan Tobacco, Avotres, and others

• Diabetes Pipeline Therapies- Enavogliflozin, Golimumab, Dasiglucagon, ThermoStem, rGDF11, IMCY-0098, Insulin icodec, CagriSema, FDC Sema-OW GIP, SemaDapa FDC, ENT-001, AG019, JTT-662, AVT-001, AZD-0186, Cotadutide, LABP-111, VX-880, Encapsulated islet cell program, CPP-1X-T, REMD-477, AT-1501, LY 3209590, Orforglipron, LY3437943, Mazdutide, Peptide YY analogue agonist, GIPR agonist long acting, GIPR Agonist Long Acting II, LY 3493269, NNC0363-0845, Diamyd, ProTrans, VC-02, OPT101, Ladarixin, ILT-101, Stem Cell Educator Therapy, ORMD-0801, Golimumab, JAG301, SQZ TAC research program, VCTX 211, and others

• Diabetes Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Dive deep into rich insights for drugs for Diabetes Market Drivers and Diabetes Market Barriers, click here @ Diabetes Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/diabetes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Diabetes: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Diabetes - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Diabetes Collaboration Deals
9. Late Stage Products (Phase III)
10. Enavogliflozin: Daewoong
11. Mid Stage Products (Phase II)
12. Golimumab: Janssen Biotech
13. Drug profiles in the detailed report…..
14. Early Stage Products (Phase II/I)
15. IMCY-0098: ImCyse
16. Drug profiles in the detailed report…..
17. Pre-clinical and Discovery Stage Products
18. ENT-001: Enthera
19. Drug profiles in the detailed report…..
20. Inactive Products
21. Diabetes Key Companies
22. Diabetes Key Products
23. Diabetes- Unmet Needs
24. Diabetes- Market Drivers and Barriers
25. Diabetes- Future Perspectives and Conclusion
26. Diabetes Analyst Views
27. Diabetes Key Companies
28. Appendix

Got Queries? Find out the related information on Diabetes Mergers and acquisitions, Diabetes Licensing Activities @ Diabetes Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/diabetes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com

This release was published on openPR.